Provided by Tiger Trade Technology Pte. Ltd.

INNOVENT BIO

98.050
+2.1502.24%
Volume:16.81M
Turnover:1.64B
Market Cap:171.10B
PE:208.62
High:99.350
Open:95.150
Low:94.800
Close:95.900
52wk High:112.700
52wk Low:69.550
Shares:1.75B
HK Float Shares:1.75B
Volume Ratio:1.98
T/O Rate:0.96%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.470
ROE:7.01%
ROA:2.23%
PB:7.06
PE(LYR):208.62
PS:9.33

Loading ...

China's Clover Biopharma H1 Revenue Drops Sharply, Flags Going-Concern Doubt

Reuters
·
Aug 26

China's Innovent Biologics H1 Revenue, Profit Rise on Strong Product Sales

Reuters
·
Aug 25

Innovent Biologics' H1 Profit Jumps 50%

MT Newswires Live
·
Aug 25

Innovent Biologics - Re-Designates Ronald Hao Xi Ede as Non-Executive Director Effective September 1, 2026

THOMSON REUTERS
·
Aug 25

Innovent Announces 2026 Interim Results and Business Updates

THOMSON REUTERS
·
Aug 25

INNOVENT BIO Reports First-Half Profit of RMB 1.253 Billion, Up 50.2% Year-on-Year

Stock News
·
Aug 25

Innovent Biologics Delivers 1H26 Net Profit of RMB 1.25 Billion on 45% Revenue Surge, Accelerates Global Pipeline

Bulletin Express
·
Aug 25

Innovent Biologics - Potential to Maintain Rapid Revenue Growth to RMB35 Bln to RMB40 Bln Total Revenue by 2030

THOMSON REUTERS
·
Aug 25

Innovent Biologics H1 FY26 IFRS Profit Climbs 50.2% to RMB 1.25 Billion; Revenue Rises 44.8% to RMB 8.62 Billion

Reuters
·
Aug 25

Innovent Biologics H1 Revenue RMB 8,617.8 Million

THOMSON REUTERS
·
Aug 25

Movement Alert|INNOVENT BIO Falls 3.13% in Regular Trading, Biotech Sector Under Pressure Ahead of Interim Results

Market Focus
·
Aug 24

Movement Alert|INNOVENT BIO Rises 4.43% in Regular Trading, Morgan Stanley Raises Target Price to HK$138.5 Amid Strong H1 Revenue Expectations

Market Focus
·
Aug 20

Movement Alert|INNOVENT BIO Rises 3.47% in Regular Trading, BlackRock Stake Increase and Strong H1 Revenue Fuel Optimism

Market Focus
·
Aug 19

Innovent Biologics (SEHK:1801), Why Is It Back In The Spotlight?

Simply Wall St.
·
Aug 19

BlackRock Expands Stake in INNOVENT BIO with Recent Share Purchase

Stock News
·
Aug 17

Movement Alert|INNOVENT BIO Rises 3.78% in Regular Trading, Strong H1 Performance and New Retail Channel Expansion Fuel Optimism

Market Focus
·
Aug 17

Spero Q2 FY26 Net Loss Widens to $9.6 Million; Revenue Posts no Revenue

Reuters
·
Aug 13

Innovent Biologics Schedules 25 Aug 2026 Board Meeting to Approve 1H26 Results

Bulletin Express
·
Aug 10

Innovent Biologics Schedules Board Meeting to Review Interim Results

Reuters
·
Aug 10

Innovent Biologics Slashes Prices on Weight-Loss Drug as Growth Concerns Mount

Deep News
·
Aug 10